X

Trial Profile

Use of 64Cu-DOTA-Trastuzumab PET Imaging and Molecular Markers for Prediction of Response to Trastuzumab and Pertuzumab-Based Neoadjuvant Therapy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Feb 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
Indications Advanced breast cancer; HER2 positive breast cancer
Focus Biomarker; Therapeutic Use

Most Recent Events

14 Feb 2024 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.
07 Aug 2023 Planned End Date changed from 30 Jun 2023 to 30 Dec 2023.
13 Feb 2023 Planned End Date changed from 31 Dec 2021 to 30 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com